Clinical Trials Sponsored by Ceregene

Total 1119 results

Celgene

Active, not recruiting

ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma

Multiple Myeloma

United States
Celgene

Completed

Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma (KarMMa)

Multiple Myeloma

United States, Canada, Belgium, France, Germany, Italy, Japan, Spain
Celgene

Completed

The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

United States, Australia, Canada, Czechia, France, Germany, Italy, Korea, Republic of, Mexico, Poland, Sweden, United Kingdom, Belgium, Brazil, Denmark, Finland, Greece, Israel, Netherlands, Norway, Portugal, Spain, Turkey
Celgene

Active, not recruiting

A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy

Leukemia, Myeloid, Acute

United States, France, Italy, Korea, Republic of, Spain, United Kingdom, Australia, Canada, Germany, Netherlands, Portugal, Switzerland, Belgium, Sweden
Celgene

Active, not recruiting

To Evaluate Efficacy and Long-term Safety of Ozanimod in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis

Colitis, Ulcerative

Japan
Celgene

Completed

A Study to Evaluate Safety and Effectiveness of Cendakimab (CC-93538) in Participants With Moderate to Severe Atopic Dermatitis

Eczema | Dermatitis, Atopic

United States, Canada, Japan, Poland, China, Czechia
Celgene

Terminated

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CC-97489 in Healthy Adult Participants

Healthy Volunteers

Belgium
Celgene

Completed

Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

Crohn Disease

United States, Spain, Australia, Austria, Bulgaria, Canada, China, Colombia, Finland, France, Georgia, Germany, Greece, Hong Kong, Hungary, Israel, Korea, Republic of, Lithuania, Netherlands, Poland, Portugal, Russian Federation, Se... and more
Celgene

Active, not recruiting

A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders

Neoplasms | Hematologic Malignancies | Hematologic Neoplasm

United Kingdom, United States
Celgene

Active, not recruiting

A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers

Neoplasms

United States, France, Australia, Canada, Italy, Korea, Republic of, Spain, United Kingdom
Celgene

Completed

A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia (FUSION NHL 001)

Lymphoma | Leukemia, Lymphocytic, Chronic, B-Cell

United States, United Kingdom, Germany, France, Italy, Netherlands, Japan
Celgene

Active, not recruiting

A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

Primary Myelofibrosis

Japan
Celgene

Active, not recruiting

A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

Multiple Myeloma

United States, Canada, Denmark, Australia, Belgium, Finland, Greece, Japan, Korea, Republic of, Spain, United Kingdom
Celgene

Completed

Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer (abound2L+)

Carcinoma, Non-Small-Cell Lung

United States, Canada, France, Germany, Italy, Spain, United Kingdom
Celgene

Completed

A Study of CC-90011 and Comparators in Participants With Prostate Cancer

Prostatic Neoplasms

United States
Celgene

Completed

A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL)

Lymphoma, Non-Hodgkin

Japan
Celgene

Terminated

A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis

Pathologic Processes | Fibrosis | Respiratory Tract Diseases | Lung Diseases | Idiopathic Pulmonary Fibrosis | Lung Diseases, Interstitial | Idiopathic Interstitial Pneumonias

United States, Australia, Colombia, United Kingdom, Russian Federation, Brazil, Germany, Canada, Greece, Romania, Taiwan, Turkey, Ukraine
Celgene

Completed

An Efficacy and Safety Study of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in Japanese Subjects Who Are Not Requiring Red Blood Cell Transfusion

Myelodysplastic Syndromes

Japan
Celgene

Completed

Use Lenalidomide (Revlimid®) in Combination With Dexamethasone in Clinical Practice for the Treatment of Newly Diagnosed Multiple Myeloma (MM) Transplant Ineligible Patients

Multiple Myeloma

Austria
Celgene

Completed

Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (OPTIMISMM)

Multiple Myeloma

United States, Spain, United Kingdom, Italy, Israel, Portugal, Germany, Turkey, Greece, Ireland, Austria, Norway, Netherlands, Denmark, Poland, France, Russian Federation, Canada, Finland, Japan, Puerto Rico, Sweden
Celgene

Completed

Pharmacokinetics of Enasidenib (CC-90007) in Participants With Mild, Moderate and Severe Hepatic Impairment

Hepatic Impairment

United States
Celgene

Completed

Study to Evaluate Safety and Tolerability of Iberdomide (CC-220) in Participants With Kidney Impairment Compared to Participants With Normal Kidney Function

Renal Insufficiency

United States
Celgene

Available

Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release

Multiple Myeloma
Celgene

Completed

Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma

Diffuse Large B-Cell Lymphoma | Multiple Myeloma | Hepatocellular Carcinoma | Non-Small Cell Lung Cancer | Glioblastoma Multiforme | Neuroendocrine Tumors of Non-Pancreatic Origin | Hormone Receptor-Positive Breast Cancer

United States, Spain, United Kingdom, France
Celgene

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CC-99677 in Healthy Adult Japanese Participants.

Healthy Volunteers

United States
Celgene

Completed

Non-interventional Study of Lenalidomide in the Clinical Routine Treatment of TD Patients With IPSS Low or Int-1 MDS and Isolated Del(5q) (PASS MDS del5q)

Myelodysplastic Syndrome

Spain, United Kingdom, Denmark, Germany, France, Greece, Italy, Sweden, Belgium, United States, Luxembourg, Norway
Celgene

Completed

Safety Study of Lenalidomide/Dexamethasone to Treat Patients With Relapsed or Refractory Multiple Myeloma (PrObe-L)

Multiple Myeloma

Portugal
Celgene

Completed

A Study to Analyze the Occurrence of Transformation From Myelodysplastic Syndrome to Acute Myeloid Leukemia in Patients With Myelodysplastic Syndrome Who Received Revlimid® 5 mg Capsules and Who Are Continuing or no Longer Continuing Revlimid Treatment

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

Japan
Celgene

Completed

A Study to Evaluate the Metabolism and Excretion of [14C]-CC-92480 in Healthy Male Participants

Healthy Volunteers

United States
Celgene

Completed

A Study to Evaluate the Relative Bioavailability of a Pediatric Granule Formulation of Ozanimod in Healthy Adult Subjects

Healthy Volunteers

United States
Celgene

Completed

Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency

Multiple Myeloma

Austria, Italy, France, Spain, Netherlands, Germany, Greece, United Kingdom
Celgene

Completed

A Study to Evaluate Potential Cytochrome P450 and Transporter Protein Interactions With CC-99677

Healthy Volunteer

United Kingdom
Celgene

Completed

A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers

Hematologic Neoplasms

Spain, United States
Celgene

Completed

A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC)

Carcinoma, Hepatocellular

United States, Spain, Italy, France
Celgene

Completed

Study of Safety and Efficacy of Avadomide (CC-122) Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors

Diffuse B-Cell Lymphoma

Canada, Spain, Belgium, United States
Celgene

Completed

Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis (RADIANCE)

Relapsing Multiple Sclerosis

Spain, United States, United Kingdom, Croatia, Serbia, Belarus, Hungary, Bulgaria, Poland, Italy, Ukraine, Greece, Belgium, Georgia, Bosnia and Herzegovina, Moldova, Republic of, Romania, Russian Federation, Slovakia, South Africa and more
Celgene

Completed

Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease

Crohn's Disease

United States, Poland, Ukraine, Hungary, Canada
Celgene

Completed

A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma

Lymphoma, Follicular | Lymphoma, Large B-Cell, Diffuse

United States
Celgene

Completed

A Study to Assess the Pharmacokinetics of CC-90001 in Subjects With Mild, Moderate, and Severe Hepatic Impairment Compared With Healthy Subjects

Hepatic Impairment

United States
Celgene

No longer available

Expanded Access for ACE-011

Myelodysplastic Syndrome

United States
Celgene

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CC-90006 in Subjects With Mild to Moderate Plaque-type Psoriasis

Psoriasis

United States, Canada
Celgene

Completed

Phase 2 Study With Abraxane (Nab®Paclitaxel) in Metastatic Colorectal Cancer

Colorectal Neoplasms

France
Celgene

Completed

A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.

Systemic Lupus Erythematosus

United States
Celgene

Completed

A Study to Estimate the Effect Sizes of HRCT Endpoints in Response to Glucocorticoid Induction Therapy in Subjects With Pulmonary Sarcoidosis

Sarcoidosis, Pulmonary

United States, United Kingdom, Netherlands
Celgene

Completed

A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma

Peripheral T-cell Lymphoma

United States, Spain, Germany, France, Czechia, Australia, Sweden, United Kingdom, Ukraine, Poland
Celgene

Completed

Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors

Melanoma | Sarcoma, Soft Tissue | Cancer | Fibrosarcoma | Neuroblastoma | Osteogenic Sarcoma | Rhabdomyosarcoma | Neoplasm | Malignant Melanoma | Tumors | Histiocytoma | Dermatofibrosarcoma | Sarcoma, Ewing's | Neoplasia | Ewing's Sarcoma | Ewing's Tumor | Sarcomas, Epitheliod | Sarcoma, Spindle Cell | Clinical Oncology | Oncology,... and other conditions

United States, Canada, Spain, France, United Kingdom, Italy, Switzerland
Celgene

Completed

Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

Taiwan
Celgene

Completed

Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer

Hematologic Malignancy | Malignant Lymphoma

United States, United Kingdom
Celgene

Terminated

Use of ABI-007 for the Prevention of Vascular Access Graft Failure in Patients Undergoing Hemodialysis

Hemodialysis Graft Dysfunction

United States
Celgene

Completed

Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Diffuse Large B-cell Lymphoma

United States, Australia, Italy, Spain, France, Austria, Sweden, Czechia, United Kingdom

3

Subscribe